186 related articles for article (PubMed ID: 26631911)
21. TYK2 in Tumor Immunosurveillance.
Karjalainen A; Shoebridge S; Krunic M; Simonović N; Tebb G; Macho-Maschler S; Strobl B; Müller M
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31936322
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
Muromoto R; Shimoda K; Oritani K; Matsuda T
Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
[TBL] [Abstract][Full Text] [Related]
23. The
Gorman JA; Hundhausen C; Kinsman M; Arkatkar T; Allenspach EJ; Clough C; West SE; Thomas K; Eken A; Khim S; Hale M; Oukka M; Jackson SW; Cerosaletti K; Buckner JH; Rawlings DJ
Front Immunol; 2019; 10():44. PubMed ID: 30740104
[TBL] [Abstract][Full Text] [Related]
24. TYK2: An Upstream Kinase of STATs in Cancer.
Wöss K; Simonović N; Strobl B; Macho-Maschler S; Müller M
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694222
[TBL] [Abstract][Full Text] [Related]
25. Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.
Vielnascher RM; Hainzl E; Leitner NR; Rammerstorfer M; Popp D; Witalisz A; Rom R; Karaghiosoff M; Kolbe T; Müller S; Rülicke T; Lassnig C; Strobl B; Müller M
Transgenic Res; 2014 Jun; 23(3):519-29. PubMed ID: 24696087
[TBL] [Abstract][Full Text] [Related]
26. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
27. Limitin, an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx.
Aoki K; Shimoda K; Oritani K; Matsuda T; Kamezaki K; Muromoto R; Numata A; Tamiya S; Haro T; Ishikawa F; Takase K; Yamamoto T; Yumioka T; Miyamoto T; Nagafuji K; Gondo H; Nagafuchi S; Nakayama K; Harada M
Exp Hematol; 2003 Dec; 31(12):1317-22. PubMed ID: 14662340
[TBL] [Abstract][Full Text] [Related]
28. Janus kinase 2 activation by the platelet-activating factor receptor (PAFR): roles of Tyk2 and PAFR C terminus.
Lukashova V; Chen Z; Duhé RJ; Rola-Pleszczynski M; Stanková J
J Immunol; 2003 Oct; 171(7):3794-800. PubMed ID: 14500680
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
Oyamada A; Ikebe H; Itsumi M; Saiwai H; Okada S; Shimoda K; Iwakura Y; Nakayama KI; Iwamoto Y; Yoshikai Y; Yamada H
J Immunol; 2009 Dec; 183(11):7539-46. PubMed ID: 19917699
[TBL] [Abstract][Full Text] [Related]
30. Identification of rare coding variants in
Motegi T; Kochi Y; Matsuda K; Kubo M; Yamamoto K; Momozawa Y
Ann Rheum Dis; 2019 Aug; 78(8):1062-1069. PubMed ID: 31118190
[TBL] [Abstract][Full Text] [Related]
31. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
32. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes.
Potla R; Koeck T; Wegrzyn J; Cherukuri S; Shimoda K; Baker DP; Wolfman J; Planchon SM; Esposito C; Hoit B; Dulak J; Wolfman A; Stuehr D; Larner AC
Mol Cell Biol; 2006 Nov; 26(22):8562-71. PubMed ID: 16982690
[TBL] [Abstract][Full Text] [Related]
33. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
Sattler M; Durstin MA; Frank DA; Okuda K; Kaushansky K; Salgia R; Griffin JD
Exp Hematol; 1995 Aug; 23(9):1040-8. PubMed ID: 7543416
[TBL] [Abstract][Full Text] [Related]
34. Expression patterns of three JAK-STAT pathway genes in feather follicle development during chicken embryogenesis.
Tao Y; Zhou X; Liu Z; Zhang X; Nie Y; Zheng X; Li S; Hu X; Yang G; Zhao Q; Mou C
Gene Expr Patterns; 2020 Jan; 35():119078. PubMed ID: 31759166
[TBL] [Abstract][Full Text] [Related]
35. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation.
Shaw MH; Freeman GJ; Scott MF; Fox BA; Bzik DJ; Belkaid Y; Yap GS
J Immunol; 2006 Jun; 176(12):7263-71. PubMed ID: 16751369
[TBL] [Abstract][Full Text] [Related]
36. Establishing the role of tyrosine kinase 2 in cancer.
Ubel C; Mousset S; Trufa D; Sirbu H; Finotto S
Oncoimmunology; 2013 Jan; 2(1):e22840. PubMed ID: 23482926
[TBL] [Abstract][Full Text] [Related]
37. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
Simma O; Zebedin E; Neugebauer N; Schellack C; Pilz A; Chang-Rodriguez S; Lingnau K; Weisz E; Putz EM; Pickl WF; Felzmann T; Müller M; Decker T; Sexl V; Stoiber D
Cancer Res; 2009 Jan; 69(1):203-11. PubMed ID: 19118004
[TBL] [Abstract][Full Text] [Related]
38. Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner.
Krishnan K; Pine R; Krolewski JJ
Eur J Biochem; 1997 Jul; 247(1):298-305. PubMed ID: 9249040
[TBL] [Abstract][Full Text] [Related]
39. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
40. JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma.
Meng L; Ding L; Yu Y; Li W
Biomed Res Int; 2020; 2020():7973568. PubMed ID: 33083484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
